SEC Form 4 · accession 0001013606-17-000104
ENDOLOGIX INC /DE/ · ELGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shari L O'Quinn
Officer — VP, Clinical & Regulatory
Period of report
May 31, 2017
Accepted (ET)
Jun 6, 2017 · 9:55 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001013606
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | May 31, 2017 | A | 18,000 | $0.00 | A | 94,356 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to PurchaseF2 | $4.82 | May 31, 2017 | A | 65,000 | A | Jun 30, 2017 | May 31, 2027 | Option to Purchase | 65,000 | 65,000 | D |
Explanation of responses
- F1Performance restricted stock unit award based on a sales milestone.
- F2Options vest ratably over forty-eight months.
Remarks
Shares granted reported on Form 4 late due to administrative error.